Not sure what you mean Are you saying that NWBO has applied for BLA to FDA and FDA has accepted their trial design. Or this is another way to BS and pump
With respect to the "patient level matched control data" of the ECAs, requested by the FDA to be included in the BLA, it should be pointed out that the fact that the mOS of the unmethylated GBM treatment group of the DCVax-L trial was not statistically different from the mOS of the unmethylated GBM patients of the ECAs, should have greatly diminished the need for patient level matched control data. The similarity between the mOS of the treatment group to the mOS of the comparable population in the ECAs, shows that the inclusion/exclusion methodologies of the DCVax-L trial was a good match for the inclusion/exclusion policies of the ECAs.
Stop being so reasonable and logical. I know I know. There is, almost, no need for individual patient-level data the summarized patient-level data should suffice. Worse. Why would the FDA want to see a control group? Everyone is different. If the FDA is so hell-bent on having a fair comparison then they should demand the sponsor to randomize twins with both GBM with equal lifestyles one for placebo and the other in the treatment. Its absurd its insane. Especially when the treatment arm has in and exclusion compared to GBM soc as with the DCVAXL trial. But you don't have to convince me Its the FDA that needs to be reasoned with.
I for one do not trust that okay its so unreasonable therefore sure sure the FDA will accept NWBO's BLA.